Apimeds Pharmaceuticals US (APUS) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biofrontera (BFRI) has outperformed Apimeds Pharmaceuticals US (APUS) over the past year, losing 9.0% versus a loss of 70.5%. Biofrontera is the larger company by market cap ($13.6 million vs $8.3 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | BFRI |
|---|---|---|
| Share price | $5.51 | $0.9188 |
| Market cap | $8.32M | $13.65M |
| 1-day change | -21.84% | -1.77% |
| YTD return | -66.40% | +61.19% |
| 1-year return | -70.53% | -9.03% |
| Forward P/E | — | 2.14 |
| EPS (TTM) | $-36.03 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $1.66 |
| 52-week low | $1.51 | $0.555 |
| Distance from 52-week high | -90.77% | -44.65% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +553.03% |
| Average volume | 3.66M | 547.45K |
| Shares outstanding | 1.51M | 14.85M |
| Employees | — | 84 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed APUS by 61.5 percentage points over the past year.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Healthcare · Drug Manufacturers - Specialty & Generic
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
APUS vs BFRI FAQ
Which is bigger, Apimeds Pharmaceuticals US or Biofrontera?
Biofrontera (BFRI) is larger, with a market capitalization of $13.65M compared with $8.32M for Apimeds Pharmaceuticals US (APUS).
Which stock has performed better over the past year, APUS or BFRI?
BFRI returned -9.03% over the past 12 months, compared with -70.53% for APUS (price return, excluding dividends). Past performance does not predict future results.
Are Apimeds Pharmaceuticals US and Biofrontera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.